Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma

Recently, a global phase III study demonstrated that nivolumab markedly improved patient outcomes in recurrent or metastatic head and neck carcinoma (RMHNC). However, the efficacy of nivolumab in patients who are ineligible for clinical trials is unknown. We investigated nivolumab efficacy in real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hori, Ryusuke, Shinohara, Shogo, Kojima, Tsuyoshi, Kagoshima, Hiroki, Kitamura, Morimasa, Tateya, Ichiro, Tamaki, Hisanobu, Kumabe, Yohei, Asato, Ryo, Harada, Hiroyuki, Kitani, Yoshiharu, Tsujimura, Takashi, Honda, Keigo, Ichimaru, Kazuyuki, Omori, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770631/
https://www.ncbi.nlm.nih.gov/pubmed/31500103
http://dx.doi.org/10.3390/cancers11091317

Ejemplares similares

Ejemplares similares